The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery (POISED)

• ClinicalTrials.gov Identifier: NCT02103270
• Recruitment Status: Completed
• First Posted: April 3, 2014
• Results First Posted: September 4, 2019
• Last Update Posted: September 4, 2019
• Sponsor: Stanford University
• Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
• Information provided by (Responsible Party): Kari Christine Nadeau, MD PhD, Stanford University

Tracking Information

• First Submitted Date: March 25, 2014
• First Posted Date: April 3, 2014
• Results First Submitted Date: April 2, 2019
• Results First Posted Date: September 4, 2019
• Last Update Posted Date: September 4, 2019
• Actual Study Start Date: April 2014
• Actual Primary Completion Date: July 25, 2018 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 13, 2019)

Passing the Week 117 DBPCFC to Peanut [ Time Frame: Week 117 - Number of participants with no clinical reactivity to peanuts ]

Number of Participants with No Clinical Reactivity to Peanuts

Original Primary Outcome Measures (submitted: March 31, 2014)

Number or participants who pass a DBPCFC after the 3 month avoidance period [ Time Frame: week 117 ]

A DBPCFC is considered a pass if there is no clinical reactivity.

Current Secondary Outcome Measures (submitted: August 13, 2019)

Passing the DBPCFC to Peanut at Week 130 [ Time Frame: Week 130 ]

Secondary endpoint: Passing the DBPCFC to peanut at 130 weeks

Original Secondary Outcome Measures (submitted: March 31, 2014)

Predictability of immune monitoring measurements [ Time Frame: 1 to 5 years ]

• Determine whether immune monitoring measurements reflecting underlying mechanisms during OIT can be used to predict responses to OIT in individual subjects and, ultimately, to improve the safety and efficacy outcomes in peanut OIT protocols.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
• Official Title: Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects

Brief Summary

Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period

Secondary Objectives:

• Identify the basic immune mechanisms which can explain the differences in the effects of OIT in desensitized vs. tolerant individuals.
• Determine whether immune monitoring measurements reflecting underlying mechanisms during OIT can be used to predict responses to OIT in individual subjects and, ultimately, to improve the safety and efficacy outcomes in peanut OIT protocols.

Detailed Description

All arms will undergo an Initial Dose Escalation (IDE) Day and updosing regimen with a maintenance phase of OIT or placebo to a maximum of 4,000 mg protein daily, as peanut flour, in the OIT groups, and to a maximum of an equivalent amount of oat flour for the placebo group. After maintenance is achieved, all subjects will begin performing DBPCFCs (staged so as to ensure safety) at Week 104 and every 13 weeks thereafter. At Week 104, individuals that reach criteria will, based on the randomization that was done at the start of the study, either stop therapy with peanut and be switched to oat flour, or will be maintained on 300 mg peanut protein per day and all placebo subjects will decrease to the equivalent volume of oat flour (approximately 600 mg oat flour) to optimize the blind. All subjects will be evaluated every 13 weeks thereafter with DBPCFCs until the end of study.

Individuals in Arm A will be defined as "clinically tolerant" if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria. Individuals in Arm A who meet the definition of "clinically tolerant" will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity.

Individuals in Arm B will be defined as "desensitized" to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study).

Individuals in Arm C will be defined as "natural loss of responsiveness" if they show no clinical reactivity at DBPCFCs (week 117 to end of study).

We plan to identify the basic immune mechanisms which can explain the differences in the effects of OIT in individuals who do or do not become clinically tolerant and to determine whether immune monitoring can predict the safety and efficacy outcomes in peanut OIT protocols.

After initial screening and enrollment, there are three phases of the study:

• Dose escalation and Build up Phase
• Maintenance phase
• Tolerance and Desensitization Testing phase Overall, 120 subjects who are eligible will undergo the Initial Dose Escalation Day. Subsequent updosing visits will occur every 2 weeks as a part of the build-up phase. They will continue to updose until they reach 4,000 mg protein daily, which is the maximum maintenance amount of protein. We expect active OIT treatment subjects to reach 4,000 mg of peanut protein between 44-78 weeks.

Treatment and Desensitization Failures:

A treatment failure will be defined as a) failure to reach 1.5 mg peanut protein (single dose) during the Initial Dose Escalation Day or b) failure to reach 1,000 mg peanut protein by week 104.

Subjects who do not meet the criteria at Week 104 and who demonstrate clinical reactivity will be considered desensitization failures.

If Arm B subjects demonstrate clinical reactivity in any DBPCFC from Week 117 to end of study, they will be considered desensitization failures.

If Arm A subjects demonstrate clinical reactivity (≥Grade 1, in any DBPCFC from Week 117 to end of study, they will be considered tolerance failures.

Treatment failures, desensitization failures, and tolerance failures will be unblinded (both participant and research staff) and will be followed until the end of the study at the specified study visits but will not undergo DBPCFCs. They will be considered in statistical analyses of the intent-to-treat population.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Single Group Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Treatment
• Condition: Peanut Allergy

Intervention

• Drug: Peanut Protein 4,000mg
  Arm A will be defined as "clinically tolerant" if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of "clinically tolerant" will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity.
  Other Name: Peanut Flour
• Drug: Oat Flour
  Arm C will be defined as "natural loss of responsiveness" if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
• Drug: Peanut Protein 300 mg
  Arm B will be defined as "desensitized" to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
  Other Name: Peanut Flour

Study Arms

• Placebo Comparator: Oat Flour 600 mg
  Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
  Intervention: Drug: Oat Flour
• Active Comparator: Peanut Protein 4,000mg
  Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
  Interventions:

  • Drug: Peanut Protein 4,000mg
  • Drug: Oat Flour
• Active Comparator: Peanut Protein 300 mg
  Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
  Interventions:

  • Drug: Oat Flour
  • Drug: Peanut Protein 300 mg

Publications *

• Wang W, Lyu SC, Ji X, Gupta S, Manohar M, Dhondalay GKR, Chinthrajah S, Andorf S, Boyd SD, Tibshirani R, Galli SJ, Nadeau KC, Maecker HT. Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy. Clin Immunol. 2020 Oct;219:108568. doi: 10.1016/j.clim.2020.108568. Epub 2020 Aug 9.
• Wright BL, Fernandez-Becker NQ, Kambham N, Purington N, Cao S, Tupa D, Zhang W, Sindher SB, Rank MA, Kita H, Katzka DA, Shim KP, Bunning BJ, Doyle AD, Jacobsen EA, Tsai M, Boyd SD, Manohar M, Chinthrajah RS. Gastrointestinal Eosinophil Responses in a Longitudinal, Randomized Trial of Peanut Oral Immunotherapy. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1151-1159.e14. doi: 10.1016/j.cgh.2020.05.019. Epub 2020 May 17.
• Chinthrajah RS, Purington N, Andorf S, Long A, O'Laughlin KL, Lyu SC, Manohar M, Boyd SD, Tibshirani R, Maecker H, Plaut M, Mukai K, Tsai M, Desai M, Galli SJ, Nadeau KC. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019 Oct 19;394(10207):1437-1449. doi: 10.1016/S0140-6736(19)31793-3. Epub 2019 Sep 12. Erratum In: Lancet. 2020 Aug 8;396(10248):380.
• Chinthrajah RS, Purington N, Andorf S, Rosa JS, Mukai K, Hamilton R, Smith BM, Gupta R, Galli SJ, Desai M, Nadeau KC. Development of a tool predicting severity of allergic reaction during peanut challenge. Ann Allergy Asthma Immunol. 2018 Jul;121(1):69-76.e2. doi: 10.1016/j.anai.2018.04.020. Epub 2018 Apr 27.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: March 31, 2014): 120
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: September 1, 2018
• Actual Primary Completion Date: July 25, 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Subject and/or parent guardian must be able to understand and provide informed consent and/or assent as applicable.
• Peanut-allergic subjects between the ages of 7-55 years old.
• Sensitivity to peanut allergen as documented by a positive skin prick test result (5 mm or greater diameter wheal relative to negative control) within 10 months preceding enrollment.
• Allergy to peanut based on a double-blind placebo-controlled oral food challenge (DBPCFC) (see Appendix 4 for scoring details) failed at a dose ≤500 mg with peanut protein within 10 months preceding enrollment.
• All female subjects of child-bearing potential will be required to provide a blood or urine sample for pregnancy testing that must be negative one week before being allowed to participate in the study.
• Subjects must plan to remain in the study area during the trial.
• Subjects must be trained on the proper use of the EpiPen (see Appendix 6) to be allowed to enroll in the study.
• Subjects with other food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study.
• Use of birth control by female subjects of child-bearing potential

Exclusion Criteria:

• Inability or unwillingness of a participant to give written informed consent or comply with study protocol
• History of cardiovascular disease
• History of other chronic disease (other than asthma, atopic dermatitis, or rhinitis) requiring therapy (e.g., heart disease, diabetes) that, in the opinion of the Principal Investigator, would represent a risk to the subject's health or safety in this study or the subject's ability to comply with the study protocol
• History of eosinophilic gastrointestinal disease
• Current participation in any other interventional study
• Subject is on 'build-up phase" of immunotherapy to another allergen (i.e., has not reached maintenance dosing)
• Severe asthma (2007 NHLBI Criteria Steps 5 or 6) at time of enrollment
• • Use of complementary and alternative medicine (CAM) treatment modalities (e.g., herbal remedies) for atopic and/or non-atopic disease within 90 days preceding Initial Dose Escalation Day (IDED) or at any time after the IDED
• Inability to discontinue antihistamines for the initial day of escalation, skin testing or OFCs
• Use of omalizumab within the past six months, or current use of other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immunomodulator therapy (not including corticosteroids)
• Use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers
• Pregnancy or lactation
• History of sensitivity to oat
• History of severe anaphylaxis to peanut with symptoms including hypotension requiring fluid resuscitation and/or the need for mechanical ventilation
• Use of investigational drugs within 24 weeks of participation
• Past or current medical problems or findings from physical assessment or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 7 Years to 55 Years (Child, Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02103270
• Other Study ID Numbers: AADCRC-STAN-001
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Kari Christine Nadeau, MD PhD, Stanford University
• Original Responsible Party: Kari Christine Nadeau, Stanford University, Principal Investigator
• Current Study Sponsor: Stanford University
• Original Study Sponsor: Same as current
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

• Principal Investigator: Kari C Nadeau, MD PhD; Stanford University

• PRS Account: Stanford University
• Verification Date: August 2019